Dental Patient Care America, Inc (DPAT) Fair Value & Analysis
Healthcare · US · Market cap $1.1M
Fair value as of: Jun 26, 2026
Analysis
Dental Patient Care America, Inc (DPAT) currently trades at $0.0445, while our model-based Fair Value estimate is $0.0463 — implying the stock looks roughly 4.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Dental Patient Care America, Inc., through its subsidiaries, provides services to dentists and the dental industry. The company organizes dentists into a co-operative model of contractually networked dental practices, allowing member dentists to access various benefits, such as programs to purchase supplies, laboratory and operating services, insurance and employee benefits programs, opportunities for profit sharing, preferential business financing, and dental practice transition funding opportunities. It also offers various dental patient marketing programs, such as organization of member dentists into a network, which offers dental care plans to employers and groups. In addition, Dental Patient Care America, Inc. offers dental benefit plans. The company was founded in 1998 and is based in Salt Lake City, Utah.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Dental Patient Care America, Inc (DPAT) undervalued?
What is the fair value of DPAT?
What is the quality score of DPAT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.